Medicaments and methods for treating cancer
Medicaments and methods for treating cancer are disclosed.
1. A method of treating neuroendocrine cancer, comprising administering to a patient in need thereof, a pharmaceutical unit dosage form comprising greater than about 500 mg of sodium trans-[tetrachlorobis(1H-indazole)ruthenate (III)]and is substantially free of indazolium hydrochloride wherein the dosage form is administered to the patient intravenously on a dosing schedule of once a week.
2. The method of claim 1 , wherein the patient is administered the dosage form once on each day 1, day 8 and day 15 of a 28-day or monthly cycle.
3. The method of claim 2 , wherein the dosage form is administered at an amount of at least about 320 mg/m 2 based on the body surface area of said patient.
4. The method of claim 3 , wherein the dosage form is administered at an amount of from about 320 mg/m 2 to about 625 mg/m 2 based on the body surface area of said patient.
5. The method of claim 1 , further comprising the step of administering to the patient a medication for preventing infusional fever prior to the administration of the dosage form.
6. The method of claim 5 , wherein the medication for preventing infusional fever is a steroid.
7. The method of claim 6 , wherein said steroid is prednisone or dexamethasone.
8. The method of claim 1 , wherein the patient plasma C max is less than about 50 μg/mL.
9. The method of claim 1 , wherein said cancer is associated with a solid tumor refractory to treatment.
10. The method of claim 1 , wherein the treating results in stable disease in the patient.
11. The method of claim 1 , wherein the pharmaceutical unit dosage form comprises from about 600 to about 1000 mg of sodium trans-[tetrachlorobis(1H-indazole)ruthenate (III)] and is substantially free of indazolium hydrochloride.
12. The method of claim 1 , wherein said unit dosage form is a kophilized powder in a vial.